Carderock Capital Management Inc. Has $5.69 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Carderock Capital Management Inc. lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,769 shares of the company’s stock after selling 718 shares during the quarter. Carderock Capital Management Inc.’s holdings in IDEXX Laboratories were worth $5,693,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in IDXX. Wealth Alliance increased its holdings in shares of IDEXX Laboratories by 9.5% during the second quarter. Wealth Alliance now owns 460 shares of the company’s stock worth $224,000 after purchasing an additional 40 shares during the period. Mercer Global Advisors Inc. ADV increased its holdings in shares of IDEXX Laboratories by 4.3% during the second quarter. Mercer Global Advisors Inc. ADV now owns 4,295 shares of the company’s stock worth $2,039,000 after buying an additional 176 shares in the last quarter. Carolinas Wealth Consulting LLC boosted its stake in shares of IDEXX Laboratories by 43.0% during the second quarter. Carolinas Wealth Consulting LLC now owns 123 shares of the company’s stock valued at $60,000 after purchasing an additional 37 shares in the last quarter. Ieq Capital LLC increased its position in IDEXX Laboratories by 4.7% in the 2nd quarter. Ieq Capital LLC now owns 7,551 shares of the company’s stock valued at $3,679,000 after acquiring an additional 342 shares during the period. Finally, Benjamin F. Edwards & Company Inc. raised its position in IDEXX Laboratories by 2.8% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,657 shares of the company’s stock worth $807,000 after purchasing an additional 45 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $419.26 on Friday. The firm has a 50-day moving average price of $423.88 and a 200-day moving average price of $458.53. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $34.33 billion, a price-to-earnings ratio of 40.43, a PEG ratio of 3.52 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. During the same quarter in the previous year, the firm posted $2.53 EPS. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. Equities analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.18% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Piper Sandler reiterated a “neutral” rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, JPMorgan Chase & Co. lowered their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $523.86.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.